Other studies highlighted that ErbB2-CAR.NK92 prolonged survival and induced reduction of primary tumors and metastasis in breast cancer and GBM xenografts, while parallel-unmodified NK92 cells were unable to inhibit tumor progression [159,167,168]. Here, ERBB2 is linked to glioblastoma.